Related Experiment Video

Updated: Jan 15, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.4K

Risks and Benefits for Sirolimus in Aging Prevention

Mallikaarjun S, Kirstein M N, Gupta A K

    Journal of Clinical Pharmacology
    |October 9, 2025
    PubMed

    Insights

    Sirolimus shows promise for anti-aging, but lacks formal guidance. Clinicians must weigh risks and benefits for off-label aging prevention use, informing patients of limited evidence.

    Area of Science:

    • Gerontology
    • Pharmacology
    • Immunology

    Background:

    • Growing public interest exists in preventing aging and age-related diseases.
    • Sirolimus, an FDA-approved drug for organ transplant recipients, possesses immune-modulating and growth-inhibitory properties.
    • Off-label use of sirolimus for aging prevention is emerging but lacks formal guidelines.

    Purpose of the Study:

    • To address the lack of formal guidance on sirolimus dosing and administration for aging prevention.
    • To provide recommendations for clinicians prescribing sirolimus off-label for anti-aging purposes.

    Main Methods:

    • Review of current literature on sirolimus and aging.
    • Analysis of its pharmacological properties and off-label applications.
    • Formulation of recommendations by the American College of Clinical Pharmacology.

    Main Results:

    • No formal policy or position paper currently exists for sirolimus in aging prevention.
    • Clinicians are advised to carefully assess the risk-benefit profile for each patient.
    • Patients must be fully informed about the off-label status and limited supporting evidence.

    Conclusions:

    • Prescribing sirolimus for aging prevention requires careful consideration due to lack of regulatory approval and robust evidence.
    • Healthcare providers should discuss available clinical evidence and ongoing trials with patients.
    • Further research is needed to establish safety, efficacy, and optimal dosing for sirolimus in aging prevention.
    Keywords:
    aginglongevitymTORsirolimus

    More Related Videos

    Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases11:20

    Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

    Published on: June 14, 2021

    4.3K
    Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

    Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

    Published on: April 12, 2021

    4.9K

    Related Concept Videos

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

    In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
    234
    Pharmacodynamics in Geriatric Patients: Effects of Age01:27

    Pharmacodynamics in Geriatric Patients: Effects of Age

    Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
    187
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.6K
    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

    Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
    196
    Drug Dosing: Geriatric Patients01:15

    Drug Dosing: Geriatric Patients

    Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
    225
    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

    As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
    227